DOCSLIB.ORG

CAY Price List 1 2021 CHF 01.03.21 Web at Final.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CAY Price List 1 2021 CHF 01.03.21 Web at Final.Xlsx CAYMAN CHEMICAL Product & Price List 1/2021 (CHF) Officially distributed by Adipogen AG Schützenstrasse 12 4410 Liestal Schweiz Tel: 061 926 60 40 Fax: 061 926 60 49 Email: [email protected] 1 CAYMAN Price List 1_2021 (CHF) CAYMAN PRODUCT & PRICE LIST 1/2021 (CHF) (01.03.21) Prod. No. Product Name Size Price (CHF) CAY-10000-1 Cyclopentenone Prostaglandin HPLC Mixture 1 ea 121.00 CAY-10001-1 Primary Eicosanoid HPLC Mixture 1 ea 121.00 CAY-10002-1 Prostaglandin HPLC Mixture 1 ea 121.00 CAY-10003-1 Vasoactive Eicosanoid HPLC Mixture 1 ea 142.00 CAY-10005-1 Prostaglandin Metabolite HPLC Mixture 1 ea 142.00 CAY-10010-1 Prostaglandin A1 1 mg 50.00 CAY-10010-5 Prostaglandin A1 5 mg 176.00 CAY-10010-10 Prostaglandin A1 10 mg 328.00 CAY-10010-50 Prostaglandin A1 50 mg 1’386.00 CAY-10013-100 Prostaglandin A1-biotin 100 ug 47.00 CAY-10013-500 Prostaglandin A1-biotin 500 ug 211.00 CAY-10013-1 Prostaglandin A1-biotin 1 mg 374.00 CAY-10013-5 Prostaglandin A1-biotin 5 mg 1’638.00 CAY-10014-500 N-Ac-Tyr-Val-Ala-Asp-CMK 500 ug 54.00 CAY-10014-1 N-Ac-Tyr-Val-Ala-Asp-CMK 1 mg 103.00 CAY-10014-5 N-Ac-Tyr-Val-Ala-Asp-CMK 5 mg 432.00 CAY-10014-10 N-Ac-Tyr-Val-Ala-Asp-CMK 10 mg 756.00 CAY-10016-1 N-Ac-Tyr-Val-Ala-Asp-CHO 1 mg 81.00 CAY-10016-5 N-Ac-Tyr-Val-Ala-Asp-CHO 5 mg 324.00 CAY-10016-10 N-Ac-Tyr-Val-Ala-Asp-CHO 10 mg 608.00 CAY-10017-500 N-Ac-Asp-Glu-Val-Asp-CHO 500 ug 65.00 CAY-10017-1 N-Ac-Asp-Glu-Val-Asp-CHO 1 mg 110.00 CAY-10017-5 N-Ac-Asp-Glu-Val-Asp-CHO 5 mg 414.00 CAY-10017-10 N-Ac-Asp-Glu-Val-Asp-CHO 10 mg 765.00 CAY-10018-1 DDMS 1 mg 101.00 CAY-10018-5 DDMS 5 mg 454.00 CAY-10018-10 DDMS 10 mg 806.00 CAY-10019-500 1-Arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (ammonium salt) 500 ug 63.00 CAY-10019-1 1-Arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (ammonium salt) 1 mg 121.00 CAY-10019-5 1-Arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (ammonium salt) 5 mg 504.00 CAY-10019-10 1-Arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (ammonium salt) 10 mg 756.00 CAY-10020-1 Prostaglandin A1 ethyl ester 1 mg 97.00 CAY-10020-5 Prostaglandin A1 ethyl ester 5 mg 437.00 CAY-10020-10 Prostaglandin A1 ethyl ester 10 mg 778.00 CAY-10021-5 Clioquinol 5 mg 34.00 CAY-10021-10 Clioquinol 10 mg 54.00 CAY-10021-50 Clioquinol 50 mg 205.00 CAY-10021-250 Clioquinol 250 mg 274.00 CAY-10022-1 F16 1 mg 16.00 CAY-10022-5 F16 5 mg 74.00 CAY-10022-10 F16 10 mg 130.00 CAY-10022-50 F16 50 mg 567.00 CAY-10023-1 (S)-AL 8810 1 mg 85.00 CAY-10023-5 (S)-AL 8810 5 mg 382.00 CAY-10023-10 (S)-AL 8810 10 mg 677.00 CAY-10024-100 Acetaminophen 100 g 34.00 CAY-10024-250 Acetaminophen 250 g 59.00 CAY-10024-500 Acetaminophen 500 g 112.00 CAY-10026-1 T0070907 1 mg 16.00 CAY-10026-5 T0070907 5 mg 74.00 CAY-10026-10 T0070907 10 mg 130.00 CAY-10026-50 T0070907 50 mg 567.00 CAY-10028-1 Pioglitazone (potassium salt) 1 mg 40.00 CAY-10028-5 Pioglitazone (potassium salt) 5 mg 81.00 CAY-10028-10 Pioglitazone (potassium salt) 10 mg 146.00 CAY-10028-50 Pioglitazone (potassium salt) 50 mg 574.00 CAY-10029-1 MK 571 1 mg 45.00 CAY-10029-5 MK 571 5 mg 101.00 CAY-10029-10 MK 571 10 mg 176.00 CAY-10029-50 MK 571 50 mg 788.00 CAY-10031-1 POV-PC 1 mg 130.00 CAY-10031-5 POV-PC 5 mg 583.00 CAY-10031-10 POV-PC 10 mg 1’037.00 CAY-10031-25 POV-PC 25 mg 2’268.00 CAY-10032-5 N-(alpha-Linolenoyl) Tyrosine 5 mg 103.00 CAY-10032-10 N-(alpha-Linolenoyl) Tyrosine 10 mg 194.00 CAY-10032-50 N-(alpha-Linolenoyl) Tyrosine 50 mg 821.00 CAY-10032-100 N-(alpha-Linolenoyl) Tyrosine 100 mg 1’436.00 CAY-10033-25 5(S),6(R)-Lipoxin A4 methyl ester 25 ug 403.00 CAY-10033-50 5(S),6(R)-Lipoxin A4 methyl ester 50 ug 767.00 CAY-10033-100 5(S),6(R)-Lipoxin A4 methyl ester 100 ug 1’451.00 CAY-10035-100 8-iso Prostaglandin A1 100 ug 45.00 CAY-10035-500 8-iso Prostaglandin A1 500 ug 146.00 CAY-10035-1 8-iso Prostaglandin A1 1 mg 248.00 CAY-10037-100 10-Nitrolinoleate 100 ug 68.00 CAY-10037-500 10-Nitrolinoleate 500 ug 308.00 CAY-10037-1 10-Nitrolinoleate 1 mg 547.00 CAY-10038-1 TMS 1 mg 20.00 CAY-10038-5 TMS 5 mg 90.00 CAY-10038-10 TMS 10 mg 158.00 2 CAYMAN Price List 1_2021 (CHF) CAY-10038-50 TMS 50 mg 693.00 CAY-10039-1 FR122047 (hydrate) 1 mg 45.00 CAY-10039-5 FR122047 (hydrate) 5 mg 113.00 CAY-10039-10 FR122047 (hydrate) 10 mg 203.00 CAY-10039-50 FR122047 (hydrate) 50 mg 900.00 CAY-10043-500 15(R)-Iloprost 500 ug 158.00 CAY-10043-1 15(R)-Iloprost 1 mg 301.00 CAY-10043-5 15(R)-Iloprost 5 mg 1’267.00 CAY-10043-10 15(R)-Iloprost 10 mg 2’218.00 CAY-10044-500 PGPC 500 ug 32.00 CAY-10044-1 PGPC 1 mg 61.00 CAY-10044-5 PGPC 5 mg 259.00 CAY-10044-10 PGPC 10 mg 454.00 CAY-10045-5 UCM707 5 mg 117.00 CAY-10045-10 UCM707 10 mg 223.00 CAY-10045-25 UCM707 25 mg 527.00 CAY-10045-50 UCM707 50 mg 936.00 CAY-10046-5 URB597 5 mg 58.00 CAY-10046-10 URB597 10 mg 110.00 CAY-10046-50 URB597 50 mg 490.00 CAY-10046-100 URB597 100 mg 922.00 CAY-10047-1 8-iso Misoprostol 1 mg 117.00 CAY-10047-5 8-iso Misoprostol 5 mg 527.00 CAY-10047-10 8-iso Misoprostol 10 mg 936.00 CAY-10049-25 5(S),6(S)-Lipoxin A4 25 ug 403.00 CAY-10049-50 5(S),6(S)-Lipoxin A4 50 ug 767.00 CAY-10049-100 5(S),6(S)-Lipoxin A4 100 ug 1’451.00 CAY-10054-1 GW 3965 (hydrochloride) 1 mg 63.00 CAY-10054-5 GW 3965 (hydrochloride) 5 mg 171.00 CAY-10054-10 GW 3965 (hydrochloride) 10 mg 252.00 CAY-10057-5 BAY-41-2272 5 mg 153.00 CAY-10057-10 BAY-41-2272 10 mg 292.00 CAY-10057-25 BAY-41-2272 25 mg 612.00 CAY-10057-50 BAY-41-2272 50 mg 1’148.00 CAY-10065-500 15-deoxy-Δ12,14-Prostaglandin A1 500 ug 140.00 CAY-10065-1 15-deoxy-Delta12,14-Prostaglandin A1 1 mg 211.00 CAY-10065-5 15-deoxy-Delta12,14-Prostaglandin A1 5 mg 983.00 CAY-10070-100 15-epi Prostaglandin A1 100 ug 45.00 CAY-10070-500 15-epi Prostaglandin A1 500 ug 158.00 CAY-10070-1 15-epi Prostaglandin A1 1 mg 225.00 CAY-10072-50 Ursolic Acid 50 mg 41.00 CAY-10072-100 Ursolic Acid 100 mg 68.00 CAY-10072-250 Ursolic Acid 250 mg 171.00 CAY-10073-1 (+)-Abscisic Acid 1 mg 29.00 CAY-10073-5 (+)-Abscisic Acid 5 mg 130.00 CAY-10073-10 (+)-Abscisic Acid 10 mg 230.00 CAY-10073-50 (+)-Abscisic Acid 50 mg 1’008.00 CAY-10075-1 CAY10452 1 mg 45.00 CAY-10075-5 CAY10452 5 mg 146.00 CAY-10075-10 CAY10452 10 mg 248.00 CAY-10075-25 CAY10452 25 mg 529.00 CAY-10080-1 16,16-dimethyl Prostaglandin A1 1 mg 126.00 CAY-10080-5 16,16-dimethyl Prostaglandin A1 5 mg 567.00 CAY-10080-10 16,16-dimethyl Prostaglandin A1 10 mg 1’008.00 CAY-10091-10 Etoricoxib 10 mg 45.00 CAY-10091-50 Etoricoxib 50 mg 180.00 CAY-10091-100 Etoricoxib 100 mg 293.00 CAY-10091-250 Etoricoxib 250 mg 675.00 CAY-10092-200 Adenosine Receptor A2A Blocking Peptide 200 ug 193.00 CAY-10096-1 SB 242084 (hydrochloride) 1 mg 67.00 CAY-10096-5 SB 242084 (hydrochloride) 5 mg 200.00 CAY-10096-10 SB 242084 (hydrochloride) 10 mg 266.00 CAY-10108-1 SC-57461A 1 mg 45.00 CAY-10108-5 SC-57461A 5 mg 158.00 CAY-10108-10 SC-57461A 10 mg 248.00 CAY-10108-25 SC-57461A 25 mg 563.00 CAY-10111-5 EA4 5 mg 131.00 CAY-10111-10 EA4 10 mg 250.00 CAY-10111-50 EA4 50 mg 1’051.00 CAY-10111-100 EA4 100 mg 1’840.00 CAY-10112-1 (±)-Enterolactone 1 mg 50.00 CAY-10112-5 (±)-Enterolactone 5 mg 227.00 CAY-10112-10 (±)-Enterolactone 10 mg 403.00 CAY-10112-50 (±)-Enterolactone 50 mg 1’764.00 CAY-10113-1 AL 8810 isopropyl ester 1 mg 103.00 CAY-10113-5 AL 8810 isopropyl ester 5 mg 463.00 CAY-10113-10 AL 8810 isopropyl ester 10 mg 821.00 CAY-10115-5 N-Oleoyl Dopamine 5 mg 63.00 CAY-10115-10 N-Oleoyl Dopamine 10 mg 121.00 CAY-10115-50 N-Oleoyl Dopamine 50 mg 504.00 CAY-10115-100 N-Oleoyl Dopamine 100 mg 882.00 CAY-10118-1 15(R)-Prostaglandin D2 1 mg 113.00 CAY-10118-5 15(R)-Prostaglandin D2 5 mg 538.00 CAY-10118-10 15(R)-Prostaglandin D2 10 mg 1’021.00 3 CAYMAN Price List 1_2021 (CHF) CAY-10120-1 CP 24,879 (hydrochloride) 1 mg 43.00 CAY-10120-5 CP 24,879 (hydrochloride) 5 mg 194.00 CAY-10120-10 CP 24,879 (hydrochloride) 10 mg 346.00 CAY-10120-50 CP 24,879 (hydrochloride) 50 mg 1’512.00 CAY-10129-1 5-trans Latanoprost (free acid) 1 mg 124.00 CAY-10129-5 5-trans Latanoprost (free acid) 5 mg 560.00 CAY-10129-10 5-trans Latanoprost (free acid) 10 mg 994.00 CAY-10131-1 24(S),25-epoxy Cholesterol 1 mg 135.00 CAY-10133-1 MK 886 (sodium salt) 1 mg 45.00 CAY-10133-5 MK 886 (sodium salt) 5 mg 135.00 CAY-10133-10 MK 886 (sodium salt) 10 mg 225.00 CAY-10133-25 MK 886 (sodium salt) 25 mg 506.00 CAY-10134-1 HQL-79 1 mg 54.00 CAY-10134-5 HQL-79 5 mg 176.00 CAY-10134-10 HQL-79 10 mg 216.00 CAY-10134-50 HQL-79 50 mg 810.00 CAY-10135-1 ICI 192605 1 mg 45.00 CAY-10135-5 ICI 192605 5 mg 135.00 CAY-10135-10 ICI 192605 10 mg 243.00 CAY-10135-25 ICI 192605 25 mg 540.00 CAY-10136-1 GPR17 (C-Term) Polyclonal Antibody 1 Vial 466.00 CAY-10137-5 Icilin 5 mg 72.00 CAY-10137-10 Icilin 10 mg 121.00 CAY-10137-50 Icilin 50 mg 554.00 CAY-10137-100 Icilin 100 mg 806.00 CAY-10138-25 (±)12-HpETE 25 ug 99.00 CAY-10138-50 (±)12-HpETE 50 ug 189.00 CAY-10138-100 (±)12-HpETE 100 ug 356.00 CAY-10139-500 Prostaglandin F2α-1-glyceryl ester 500 ug 63.00 CAY-10139-1 Prostaglandin F2alpha-1-glyceryl ester 1 mg 108.00 CAY-10139-5 Prostaglandin F2alpha-1-glyceryl ester 5 mg 504.00 CAY-10140-1 Prostaglandin E2-1-glyceryl ester 1 mg 130.00 CAY-10140-5 Prostaglandin E2-1-glyceryl ester 5 mg 583.00 CAY-10140-10 Prostaglandin E2-1-glyceryl ester 10 mg 1’037.00 CAY-10141-50 15-deoxy-Delta12,14-Prostaglandin J2-biotin 50 ug 189.00 CAY-10141-100 15-deoxy-Delta12,14-Prostaglandin J2-biotin 100 ug 360.00 CAY-10141-500 15-deoxy-Delta12,14-Prostaglandin J2-biotin 500 ug 1’512.00 CAY-10155-1 BM 567 1 mg 86.00 CAY-10155-5 BM 567 5 mg 389.00 CAY-10155-10 BM 567 10 mg 691.00 CAY-10156-1 BAY-u3405 1 mg 45.00 CAY-10156-5 BAY-u3405 5 mg 140.00 CAY-10156-10 BAY-u3405 10 mg 243.00 CAY-10156-50 BAY-u3405 50 mg 1’103.00
Load more

Recommended publications
  • Substances That Target Tumor Metabolism
    Biomedical Research 2011; 22 (2): 132-166 1181_On the metabolic origin of cancer: substances that target tumor metabolism. Maurice Israël 1 and Laurent Schwartz 2 1Biorebus 38 rue de Bassano 75008 Paris ; and 2 Av Aristide Briand 91440 Bures sur Yvette. France. 2LIX : Ecole Polytechnique Palaiseau France ; and Hôpital Pitié- Salpêtrière, service de radiothérapie, 75013 Paris. Abstract. Work from our group and others clearly suggest the key role of altered metabolism in cancer. The goal of this review is to summarize current knowledge on cancer metabolism, draw hy- pothesis explaining metabolic alterations and associated gene changes. Most importantly, we indicate a list of possible pharmacological targets. In short, tumor metabolism displays mixed glycolysis and neoglucogenesis features; most glycolitic enzymes are activate, but the pyruvate kinase and the pyruvate deshydrogenase are inhibited. This would result from an activation of their specific kinases, or from the inactivation of phosphatases, such as PP2A, regulated by me- thylation. In parallel, the phosphatase failure would enhance “tyrosine kinase receptor” signals, as occurs with oncogenes. Such signaling pathways are similar to those activated by insuline, or IGF- Growth hormone; they control mitosis, cell survival, carbohydrate metabolism. If for some reason, their regulation fails (oncogenes, PP2A methylation deficit, enhanced kinases…) a typical tumor metabolism starts the carcinogenic process. We also describe changes in the citric acid- urea cycles, polyamines, and show how body stores feed tumor metabolic pathways above and below “bottlenecks” resulting from wrongly switched enzymes. Studying the available lit- erature, we list a number of medications that target enzymes that are essential for tumor cells.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information CNQX Item No. 14618 CAS Registry No.: 115066-14-3 Formal Name: 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-6- quinoxalinecarbonitrile H Synonyms: 6-cyano-7-Nitroquinoxaline-2,3-dione, NC N O FG 9065 MF: C9H4N4O4 FW: 232.2 O O N N Purity: ≥98% 2 Stability: ≥2 years at -20°C H Supplied as: A crystalline solid λ UV/Vis.: max: 217, 275, 315 nm Laboratory Procedures For long term storage, we suggest that CNQX be stored as supplied at -20°C. It should be stable for at least two years. CNQX is supplied as a crystalline solid. A stock solution may be made by dissolving the CNQX in the solvent of choice. CNQX is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CNQX in these solvents is approximately 5 and 12 mg/ml, respectively. CNQX is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CNQX should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CNQX has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. CNQX is a competitive, non-NMDA glutamate receptor antagonist (IC50s = 0.3 and 1.5 μM for AMPA and kainate 1,2 receptors, respectively, versus IC50 = 25 μM for NMDA receptors). This compound has been used to specifically target AMPA and kainate receptor responses and thus differentiate from that of NMDA receptors.
    [Show full text]
  • Synthetic Cannabinoids-1) IMMUNALYSIS DIRECT ELISA Kit for Forensic Matrices
    K2 (Synthetic IMMUNALYSIS Cannabinoids-1) DIRECT ELISA Kit for forensic matrices JWH-018 Demonstrates significant cross reactivity with the major metabolites of JWH-018, JWH-073, Schedule I Controlled Substances: JWH-018, JWH-073, JWH-200, JWH-019, JWH-200 and AM-2201. JWH-122, JWH-398, JWH-081, JWH-250, JWH-203 CP-47,497, CP-47,497 C8, HU-210, HU-211, AM-2201, AM-694, RCS-4 (SR-19), RCS-8 (SR-18) Street Names: Spice, K2, Genie, Yucatan Fire, Skunk, Sence, Smoke, ChillX, Highdi’s Almdröhner, Earth Impact, Gorillaz, Galaxy Gold, Space Truckin, Solar Flare, Moon Rocks, Blue Lotus, Aroma, Scope, Sky, OG Potpourri, Bliss, Black Momba, Bombay Blue, Fake Weed, and Zohai. Urine About Synthetic Cannabinoids: Spice or K2 is a mixture of herbs and spices treated with synthetic compounds similar to THC that is typically sold in head shops, tobacco shops or over the internet. Though not structurally related, K2 mimics the psychoactive stimulant properties of THC but can be 100 to 800 times more potent than THC.1 Administration: Synthetic Cannabinoid products are usually smoked in joints or pipes, and sometimes made into tea.2 Effects: Psychological effects are similar to those of marijuana and include paranoia, panic attacks and giddiness. Physiological effects include increased heart rate and high blood pressure. Long-term effects are not known.2 1. Devane, W. A. et al. A novel probe for the cannabi- noid receptor. Journal of Medical Chemistry 35 (11): 2065–2069 (1992). 2. Drug Enforcement Administration; www.dea.gov. Tel 909.482.0840 | Toll Free
    [Show full text]
  • An Investigation Into Pro-Apoptotic Targets in Experimental Glaucoma and the Neuroprotective Effects of Ginkgo Biloba in Retinal Ganglion Cells
    An investigation into pro-apoptotic targets in experimental glaucoma and the neuroprotective effects of Ginkgo biloba in retinal ganglion cells Abeir Baltmr MB ChB, FRCS (Glasg) A thesis submitted to University College London for the degree of Doctor of Medicine (Research) 2012 Glaucoma and Retinal Neurodegeneration Research Group Visual Neuroscience Institute of Ophthalmology 1 Declaration I, Abeir Baltmr, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Abeir Baltmr 2 Abstract Ginkgo biloba has been advocated as a neuroprotective agent for several years in glaucoma. In this study, immunohistochemistry was used to identify known potential molecular targets of Ginkgo biloba related to retinal ganglion cell (RGC) apoptosis in experimental glaucoma, including amyloid precursor protein (APP), Aß, cytochrome c, caspase-3 and tumor necrosis factor receptor-1 (TNF-R1). Furthermore, using apoptotic inducers related to mechanisms implicated in glaucoma, namely Dimethyl sulphoxide (DMSO), ultraviolet C (UVC) and Sodium Azide (NaN3), the effects of the terpenoid fraction of Ginkgo biloba (Ginkgolide A, Ginkgolide B and Bilobalide) were investigated separately in cultured retinal ganglion cells (RGC-5). Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and morphological analysis of DMSO treated RGC-5 was performed using Hoechst 33342 stain. Immunohistochemistry showed a strong inverse correlation between Aß and APP in ocular hypertension (OHT) animals, with APP and Aß accumulation peaking at 1 and 12 weeks after intraocular pressure (IOP) elevation respectively. Cytochrome c and TNF-R1 expression peaked at 3 weeks, and active caspase 3 activity at 12 weeks after IOP elevation.
    [Show full text]
  • Serum Enterolactone
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Julkari Annamari Kilkkinen SERUM ENTEROLACTONE D E T E R M I N A N T S A N D A S S O C I A T I O N S W I T H B R E A S T A N D P R O S T A T E C A N C E R S A C A D E M I C D I S S E R T A T I O N To be presented with the permission of the Faculty of Medicine, University of Helsinki, for public examination in Auditorium XII, University Main Building, on June 11th, 2004, at 12 noon. National Public Health Institute, Helsinki, Finland and Department of Public Health, University of Helsinki, Finland Helsinki 2004 P u b l i c a t i o n s o f t h e N a t i o n a l P u b l i c H e a l t h I n s t i t u t e K T L A 1 0 / 2 0 0 4 Copyright National Public Health Institute Julkaisija-Utgivare-Publisher Kansanterveyslaitos (KTL) Mannerheimintie 166 00300 Helsinki Puh. vaihde (09) 474 41, telefax (09) 4744 8408 Folkhälsoinstitutet Mannerheimvägen 166 00300 Helsingfors Tel. växel (09) 474 41, telefax (09) 4744 8408 National Public Health Institute Mannerheimintie 166 FIN-00300 Helsinki, Finland Telephone +358 9 474 41, telefax +358 9 4744 8408 ISBN 951-740-448-4 ISSN 0359-3584 ISBN 951-740-449-2 (pdf) ISSN 1458-6290 (pdf) Hakapaino Oy Helsinki 2004 S u p e r v i s e d b y Professor Pirjo Pietinen Department of Epidemiology and Health Promotion National Public Health Institute, Helsinki, Finland Professor Jarmo Virtamo Department of Epidemiology and Health Promotion National Public Health Institute, Helsinki, Finland R e v i e w e d b y Associate Professor Sari
    [Show full text]
  • Illuminating Dna Packaging in Sperm Chromatin: How Polycation Lengths, Underprotamination and Disulfide Linkages Alters Dna Condensation and Stability
    University of Kentucky UKnowledge Theses and Dissertations--Chemistry Chemistry 2019 ILLUMINATING DNA PACKAGING IN SPERM CHROMATIN: HOW POLYCATION LENGTHS, UNDERPROTAMINATION AND DISULFIDE LINKAGES ALTERS DNA CONDENSATION AND STABILITY Daniel Kirchhoff University of Kentucky, [email protected] Digital Object Identifier: https://doi.org/10.13023/etd.2019.233 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Kirchhoff, Daniel, "ILLUMINATING DNA PACKAGING IN SPERM CHROMATIN: HOW POLYCATION LENGTHS, UNDERPROTAMINATION AND DISULFIDE LINKAGES ALTERS DNA CONDENSATION AND STABILITY" (2019). Theses and Dissertations--Chemistry. 112. https://uknowledge.uky.edu/chemistry_etds/112 This Doctoral Dissertation is brought to you for free and open access by the Chemistry at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Chemistry by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • ) (51) International Patent Classification: Columbia V5G 1G3
    ) ( (51) International Patent Classification: Columbia V5G 1G3 (CA). PANDEY, Nihar R.; 10209 A 61K 31/4525 (2006.01) C07C 39/23 (2006.01) 128A St, Surrey, British Columbia V3T 3E7 (CA). A61K 31/05 (2006.01) C07D 405/06 (2006.01) (74) Agent: ZIESCHE, Sonia et al.; Gowling WLG (Canada) A61P25/22 (2006.01) LLP, 2300 - 550 Burrard Street, Vancouver, British Colum¬ (21) International Application Number: bia V6C 2B5 (CA). PCT/CA2020/050165 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection av ailable) . AE, AG, AL, AM, 07 February 2020 (07.02.2020) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 16/270,389 07 February 2019 (07.02.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (63) Related by continuation (CON) or continuation-in-part SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (CIP) to earlier application: TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. US 16/270,389 (CON) (84) Designated States (unless otherwise indicated, for every Filed on 07 Februaiy 2019 (07.02.2019) kind of regional protection available) .
    [Show full text]
  • Programme & Abstracts
    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Natural Products As Alternative Choices for P-Glycoprotein (P-Gp) Inhibition
    Review Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition Saikat Dewanjee 1,*, Tarun K. Dua 1, Niloy Bhattacharjee 1, Anup Das 2, Moumita Gangopadhyay 3, Ritu Khanra 1, Swarnalata Joardar 1, Muhammad Riaz 4, Vincenzo De Feo 5,* and Muhammad Zia-Ul-Haq 6,* 1 Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India; [email protected] (T.K.D.); [email protected] (N.B.); [email protected] (R.K.); [email protected] (S.J.) 2 Department of Pharmaceutical Technology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 3 Department of Bioechnology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 4 Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan; [email protected] 5 Department of Pharmacy, Salerno University, Fisciano 84084, Salerno, Italy 6 Environment Science Department, Lahore College for Women University, Jail Road, Lahore 54600, Pakistan * Correspondence: [email protected] (S.D.); [email protected] (V.D.F.); [email protected] (M.Z.-U.-H.) Academic Editor: Maria Emília de Sousa Received: 11 April 2017; Accepted: 15 May 2017; Published: 25 May 2017 Abstract: Multidrug resistance (MDR) is regarded as one of the bottlenecks of successful clinical treatment for numerous chemotherapeutic agents. Multiple key regulators are alleged to be responsible for MDR and making the treatment regimens ineffective. In this review, we discuss MDR in relation to P-glycoprotein (P-gp) and its down-regulation by natural bioactive molecules. P-gp, a unique ATP-dependent membrane transport protein, is one of those key regulators which are present in the lining of the colon, endothelial cells of the blood brain barrier (BBB), bile duct, adrenal gland, kidney tubules, small intestine, pancreatic ducts and in many other tissues like heart, lungs, spleen, skeletal muscles, etc.
    [Show full text]
  • Aloe Ferox 117 Table 9: Phytochemical Constituents of Different Extracts of Aloe CIM- Sheetal Leaves 119
    International Journal of Scientific & Engineering Research ISSN 2229-5518 1 Morphological, in vitro, Biochemical and Genetic Diversity Studies in Aloe species THESIS SUBMITTED TO OSMANIA UNIVERSITY FOR THE AWARD OF DOCTOR OF PHILOSOPHY IN GENETICS IJSER By B. CHANDRA SEKHAR SINGH DEPARTMENT OF GENETICS OSMANIA UNIVERSITY HYDERABAD - 500007, INDIA JULY, 2015 IJSER © 2018 http://www.ijser.org International Journal of Scientific & Engineering Research ISSN 2229-5518 2 DECLARATION The investigation incorporated in the thesis entitled “Morphological, in vitro, Biochemical and Genetic Diversity Studies in Aloe species’’ was carried out by me at the Department of Genetics, Osmania University, Hyderabad, India under the supervision of Prof. Anupalli Roja Rani, Osmania University, Hyderabad, India. I hereby declare that the work is original and no part of the thesis has been submitted for the award of any other degree or diploma prior to this date. IJSER Date: (Bhaludra Chandra Sekhar Singh) IJSER © 2018 http://www.ijser.org International Journal of Scientific & Engineering Research ISSN 2229-5518 3 DEDICATION I dedicateIJSER this work to my beloved and beautiful wife B. Ananda Sekhar IJSER © 2018 http://www.ijser.org International Journal of Scientific & Engineering Research ISSN 2229-5518 4 Acknowledgements This dissertation is an outcome of direct and indirect contribution of many people, which supplemented my own humble efforts. I like this opportunity to mention specifically some of them and extend my gratefulness to other well wisher, known and unknown. I feel extremely privileged to express my veneration for my superviosor Dr. Anupalli Roja Rani, Professor and Head, Department of Genetics, Osmania University, Hyderabad. Her whole- hearted co-operation, inspiration and encouragement rendered throughout made this in carrying out the research and writing of this thesis possible.
    [Show full text]
  • Various Species, Mainly Aloe Ferox Miller and Its Hybrids)
    European Medicines Agency Evaluation of Medicines for Human Use London, 5 July 2007 Doc. Ref: EMEA/HMPC/76313/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON ALOE BARABADENSIS MILLER AND ALOE (VARIOUS SPECIES, MAINLY ALOE FEROX MILLER AND ITS HYBRIDS) Aloe barbadensis Miller (barbados aloes) Herbal substance Aloe [various species, mainly Aloe ferox Miller and its hybrids] (cape aloes) the concentrated and dried juice of the leaves, Herbal Preparation standardised; standardised herbal preparations thereof Pharmaceutical forms Herbal substance for oral preparation Rapporteur Dr C. Werner Assessor Dr. B. Merz Superseded 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS I. Introduction 3 II. Clinical Pharmacology 3 II.1 Pharmacokinetics 3 II.1.1 Phytochemical characterisation 3 II.1.2 Absorption, metabolism and excretion 4 II.1.3 Progress of action 5 II.2 Pharmacodynamics 5 II.2.1 Mode of action 5 • Laxative effect 5 • Other effects 7 II.2.2 Interactions 8 III. Clinical Efficacy 9 III.1 Dosage 9 III.2 Clinical studies 9 Conclusion 10 III.3 Clinical studies in special populations 10 III.3.1 Use in children 10 III.3.2. Use during pregnancy and lactation 10 III.3.3. Conclusion 13 III.4 Traditional use 13 IV. Safety 14 IV.1 Genotoxic and carcinogenic risk 14 IV.1.1 Preclinical Data 14 IV.1.2 Clinical Data 18 IV.1.3 Conclusion 20 IV.2 Toxicity 20 IV.3 Contraindications 21 IV.4 Special warnings and precautions for use 21 IV.5 Undesirable effects 22 IV.6 Interactions 22 IV.7 Overdose 23 V.
    [Show full text]